Mutations in the 3'-PPT Lead to HIV-1 Replication without Integration.
HIV-1
integrase
integration
resistance
unintegrated viral DNA
Journal
Journal of virology
ISSN: 1098-5514
Titre abrégé: J Virol
Pays: United States
ID NLM: 0113724
Informations de publication
Date de publication:
27 07 2022
27 07 2022
Historique:
pubmed:
28
6
2022
medline:
30
7
2022
entrez:
27
6
2022
Statut:
ppublish
Résumé
Integration of the reverse-transcribed genome is a critical step of the retroviral life cycle. Strand-transfer inhibitors (INSTIs) used for antiretroviral therapy inhibit integration but can lead to resistance mutations in the integrase gene, the enzyme involved in this reaction. A significant proportion of INSTI treatment failures, particularly those with second-generation INSTIs, show no mutation in the integrase gene. Here, we show that replication of a selected dolutegravir-resistant virus with mutations in the 3'-PPT (polypurine tract) was effective, although no integrated viral DNA was detected, due to the accumulation of unintegrated viral DNA present as 1-LTR circles. Our results show that mutation in the 3'-PPT leads to 1-LTR circles and not linear DNA as classically reported. In conclusion, our data provide a molecular basis to explain a new mechanism of resistance to INSTIs, without mutation of the integrase gene and highlights the importance of unintegrated viral DNA in HIV-1 replication.
Identifiants
pubmed: 35758669
doi: 10.1128/jvi.00676-22
pmc: PMC9327692
doi:
Substances chimiques
DNA, Viral
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0067622Références
J Virol. 2013 Dec;87(23):12701-20
pubmed: 24049167
Mol Ther. 2011 Mar;19(3):547-56
pubmed: 21157436
Int J Biochem Cell Biol. 2004 Sep;36(9):1752-66
pubmed: 15183342
Retrovirology. 2011 Jul 01;8:52
pubmed: 21722380
Retrovirology. 2016 Jan 05;13:1
pubmed: 26728316
Front Microbiol. 2017 Jan 11;7:2165
pubmed: 28123383
Viruses. 2021 Dec 14;13(12):
pubmed: 34960770
Methods Mol Biol. 2005;304:139-54
pubmed: 16061972
J Virol. 2021 Jun 10;95(13):e0028521
pubmed: 33883218
Science. 2001 Aug 24;293(5534):1503-6
pubmed: 11520990
mBio. 2020 Jun 2;11(3):
pubmed: 32487757
mBio. 2021 Jan 12;12(1):
pubmed: 33436439
EMBO J. 2001 Jun 15;20(12):3272-81
pubmed: 11406603
J Infect Dis. 2018 Nov 5;218(12):2020
pubmed: 30085190
J Virol. 2001 Sep;75(17):7944-55
pubmed: 11483739
Retrovirology. 2015 Mar 12;12:24
pubmed: 25808736
Retrovirology. 2013 Aug 13;10:87
pubmed: 23938039
Science. 2000 Jan 28;287(5453):646-50
pubmed: 10649997
Lancet HIV. 2017 Dec;4(12):e547-e554
pubmed: 29107562
Antimicrob Agents Chemother. 2014 Oct;58(10):6101-10
pubmed: 25092689
Curr Opin Infect Dis. 2013 Feb;26(1):43-9
pubmed: 23242340
J Biol Chem. 1996 Mar 8;271(10):5393-7
pubmed: 8621393
Antimicrob Agents Chemother. 2021 May 18;65(6):
pubmed: 33722887
Lancet HIV. 2015 Apr;2(4):e127-36
pubmed: 26424673
Curr Infect Dis Rep. 2013 Feb;15(1):85-100
pubmed: 23180144
mBio. 2017 Sep 26;8(5):
pubmed: 28951475
J Antimicrob Chemother. 2022 Feb 23;77(3):574-577
pubmed: 34894227